Concepedia

Michael Thutewohl

MT

Statistics

Publications

12

Citations

378

H-Index

12

Active since

1999

Affiliations

Max Planck Institute of Molecular Physiology(Current)

Max Planck Society

AstraZeneca (United Kingdom)

Merck Serono S.A. (Switzerland)

Bayer (Germany)

Michael Thutewohl is an author at Max Planck Institute of Molecular Physiology specializing in medicinal chemistry, drug discovery, and chemistry.

Publications per year

1999–2010

12

Publications

12

Identification and Specificity Profiling of Protein Prenyltransferase Inhibitors Using New Fluorescent Phosphoisoprenoids

Beatrice Dursina, Reinhard Reents, Christine Delon et al. · Journal of the American Chemical Society · 2006 · 81 citations

, , +13

Manumycin A and Its Analogues Are Irreversible Inhibitors of Neutral Sphingomyelinase

Christoph Arenz, Michael Thutewohl, Oliver Block et al. · ChemBioChem · 2001 · 73 citations

, , +8

Design and Synthesis of Potent and Selective Azaindole‐Based Rho Kinase (ROCK) Inhibitors

Hartmut Schirok, Raimund Kast, Santiago Figueroa‐Pérez et al. · ChemMedChem · 2008 · 39 citations · Full text

, , +17

Identification of hPin1 inhibitors that induce apoptosis in a mammalian Ras transformed cell line

Michael Thutewohl, Claudia Christner, Thomas Tradler et al. · Chemical Communications · 2004 · 31 citations

, , +9

Solid-Phase Synthesis and Biological Evaluation of a Pepticinnamin E Library

Michael Thutewohl, Lars Kissau, Boriana Popkirova et al. · Angewandte Chemie International Edition · 2002 · 27 citations

, , +12

1–5 of 12